B-type natriuretic peptide - Not only a biomarker

European Respiratory Disease

Volumn 7, Issue 2, 2011, Pages 80-82

  Cazzola, Mario ^a,b   Matera, Maria Gabriella ^c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

B type natriuretic peptide; Biomarker; Bronchial relaxant effects; Heart failure; Human isolated bronchi; Pulmonary diseases

Indexed keywords

EID: 84870211254     PISSN: 17545552     EISSN: 17545560     Source Type: Journal    
DOI: None     Document Type: Editorial

References (44)

1. Yasue H, Yoshimura M, Sumida H, et al., Localization and mechanism of secretion of B-type natriureticpeptide in comparison with those of A-type natriuretic peptide in normal subjects and patientswith heart failure, Circulation, 1994;90(1):195-203.
2. Taylor DR, Using biomarkers in the assessment of airways disease, J Allergy Clin Immunol, (in press).
3. Cazzola M, Novelli G, Biomarkers in COPD, Pulm Pharmacol Ther, 2010;23(6):493-500.
4. Hunt SA, Abraham WT, Chin MH, et al., 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed inCollaboration With the International Society for Heart and Lung Transplantation, Circulation, 2009;119(14):391-479.
5. Mohammed AA, Januzzi JL Jr, Natriuretic peptides in the diagnosis and management of acute heart failure, Heart Fail Clin, 2009;5(4):489-500.
6. Cowie MR, Struthers AD, Wood DA, et al., Value of natriuretic peptides in assessment of patients withpossible new heart failure in primary care, Lancet, 1997;350(9088):1349-53.
7. Januzzi JL Jr, Camargo CA, Anwaruddin S, et al., The Nterminal Pro-BNP Investigation of Dyspnea in the emergency department (PRIDE) study, Am J Cardiol, 2005; 95(8):948-54.
8. Maisel AS, Krishnaswamy P, Nowak RM, et al., Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure, N Engl J Med, 2002;347(3):161-7.
9. Januzzi JL, Jr, van Kimmenade RRJ, Lainchbury JG, et al., NTproBNP testing for diagnosis and short-term prognosis in acute congestive heart failure: an international pooled analysis of 1256 patients. The International Collaborative of NT-proBNP (ICON) Study, Eur Heart J, 2006;27(3):330-7.
10. Mueller C, Laule-Kilian K, Schindler C, et al., Costeffectiveness of B-type natriuretic peptide testing in patients with acute dyspnea, Arch Intern Med, 2006;166(10):1081-7.
11. Moe GW, Howlett J, Januzzi JL, et al., N-terminal pro-B-type natriuretic peptide testing improves themanagement of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study, Circulation, 2007;115(24):3103-10.
12. Wang TJ, Larson MG, Levy D, et al., Plasma natriuretic peptide levels and the risk of cardiovascular events and death, N Engl J Med, 2004;350(7):655-63.
13. Yap LB, Mukerjee D, Timms PM, et al., Natriuretic peptides, respiratory disease, and the right heart, Chest, 2004;126(4):1330-6.
14. Ishii J, Nomura M, Ito M, et al., Plasma concentration of brain natriuretic peptide as a biochemical marker for the evaluation of right ventricular overload and mortality in chronic respiratory disease, Clin Chim Acta, 2000;301(1-2):19-30.
15. Leuchte HH, Neurohr C, Baumgartner R, et al., Brain natriuretic peptide and exercise capacity in lungfibrosis and pulmonary hypertension, Am J Respir Crit Care Med, 2004;170(4):360-5.
16. Yano S, Kobayashi K, Kato K, Ikeda, T, [The study of pulmonary hypertension and plasma BNP values in respiratory diseases], Nihon Kokyuki Gakkai Zasshi, 2006;44(2):99-103.
17. Budweiser S, Luchner A, Jörres RA, et al., NT-proBNP in chronic hypercapnic respiratory failure: a marker of disease severity, treatment effect and prognosis, Respir Med, 2007;101(9):2003-10.
18. Bando M, Ishii Y, Sugiyama Y, Kitamura S, Elevated plasma brain natriuretic peptide levels in chronicrespiratory failure with cor pulmonale, Respir Med, 1999;93(7):507-14.
19. Silver MA, Maisel A, Yancy CW, et al., BNP Consensus Panel 2004: a clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases, Congest Heart Fail, 2004;10(5 Suppl. 3):1-30.
20. Bozkanat E, Tozkoparan E, Baysan O, et al., The significance of elevated brain natriuretic peptide levels in chronic obstructive pulmonary disease, J Int Med Res, 2005;33(5):537-44.
21. Inoue Y, Kawayama T, Iwanaga T, Aizawa H, High plasma brain natriuretic peptide levels in stable COPDwithout pulmonary hypertension or cor pulmonale, Intern Med, 2009;48(11):503-12.
22. Gemici G, Erdim R, Celiker A, et al., B-type natriuretic peptide levels in patients with COPD and normal right ventricular function, Adv Ther, 2008;25(7):674-80.
23. van Gestel YR, Goei D, Hoeks SE, et al., Predictive value of NT-proBNP in vascular surgery patients with COPD and normal left ventricular systolic function, COPD, 2010;7(1):70-5.
24. Gale CP, White JE, Hunter A, et al., Predicting mortality and hospital admission in patients with COPD: significance of NT pro-BNP, clinical and echocardiographic assessment, J Cardiovasc Med (Hagerstown), 2011;12(9):613-8.
25. Stolz D, Breidthardt T, Christ-Crain M, et al., Use of B-type natriuretic peptide in the risk stratification of acute exacerbations of COPD, Chest, 2008;133(5):1088-94.
26. Chang CL, Robinson SC, Mills GD, et al., Biochemical markers of cardiac dysfunction predict mortalityin acute exacerbations of COPD, Thorax, 2011;66(9):764-8.
27. Medina AM, Marteles MS, Sáiz EB, et al., Prognostic utility of NT-proBNP in acute exacerbations of chronic pulmonary diseases, Eur J Intern Med, 2011;22(2):167-71.
28. Rutten FH, Cramer MJ, Zuithoff NP, et al., Comparison of B-type natriuretic peptide assays foridentifying heart failure in stable elderly patients with a clinical diagnosis of chronic obstructivepulmonary disease, Eur J Heart Fail, 2007;9(6-7):651-9.
29. Zhao L, Hughes JM, Winter RJ, Effects of natriuretic peptides and neutral endopeptidase 24.11 inhibition in isolated perfused rat lung, Am Rev Respir Dis, 1992;146(5 pt 1):1198-201.
30. Cargill RI, Lipworth BJ, Acute effects of ANP and BNP on hypoxic pulmonary vasoconstriction in humans, Br J Clin Pharmacol, 1995;40(6):585-90.
31. Cargill RI, Lipworth BJ, Atrial natriuretic peptide and brain natriuretic peptide in cor pulmonale. Hemodynamic and endocrine effects, Chest, 1996;110(5):1220-5.
32. Arjona AA, Hsu CA, Wrenn DS, Hill, NS, Effects of natriuretic peptides on vascular smooth-muscle cells derived from different vascular beds, Gen Pharmacol Vasc Syst, 1997;28(3):387-92
33. Klinger JR, Warburton RR, Pietras L, Hill NS, Brain natriuretic peptide inhibits hypoxic pulmonary hypertension in rats, J Appl Physiol, 1998;84(5):1646-52.
34. Leuchte HH, Michalek J, Soenmez O, et al., Preserved pulmonary vasodilative properties of aerosolizedbrain natriuretic peptide, Pulm Pharmacol Ther, 2009;22(6):548-53.
35. Hulks G, Jardine AG, Connell JM, Thomson NC, Effect of atrial natriuretic factor on bronchomotor tonein the normal human airway, Clin Sci (Lond), 1990;79(1):51-5.
36. Takagi K, Araki N, Relaxant effects of brain natriuretic peptide on guinea-pig tracheal smooth muscle, Clin Exp Pharmacol Physiol, 1993;20(4):239-43.
37. Ohbayashi H, Suito H, Takagi K, Compared effects of natriuretic peptides on ovalbumin-induced asthmatic model, Eur J Pharmacol, 1998;346(1):55-64.
38. Akerman MJ, Yaegashi M, Khiangte Z, et al., Bronchodilator effect of infused B-type natriuretic peptide in asthma, Chest, 2006;130(1):66-72.
39. Matera MG, Calzetta L, Parascandolo V, et al., Relaxant effect of brain natriuretic peptide in nonsensitized and passively sensitized isolated human bronchi, Pulm Pharmacol Ther, 2009;22(6):478-82.
40. Matera MG, Calzetta L, Passeri D, et al., Epithelium integrity is crucial for the relaxant activity of brain natriuretic peptide in human isolated bronchi, Br J Pharmacol, 2011;163(8):1740-54.
41. Potter LR, Abbey-Hosch S, Dickey DM, Natriuretic peptides, their receptors, and cyclic guanosine monophosphatedependent signaling functions, Endocr Rev, 2006;27(1):47-72.
42. Hamad AM, Range S, Holland E, Knox AJ, Regulation of cGMP by soluble and particulate guanylyl cyclases in cultured human airway smooth muscle, Am J Physiol, 1997;273(4 pt 1):L807-L13.
43. Hamad AM, Clayton A, Islam B, Knox AJ, Guanylyl cyclases, nitric oxide, natriuretic peptides, and airway smooth muscle function, Am J Physiol Lung Cell Mol Physiol, 2003;285(5):L973-L83.
44. Matera MG, Page CP, Cazzola M, Novel bronchodilators for the treatment of chronic obstructive pulmonary disease, Trends Pharmacol Sci, 2011;32(8):495-506.